Agentes tópicos para prevenção de radiodermatite em pacientes com câncer: revisão sistemática

Gilma Teresa Guimarães Perse; Rafael Tavares Jomar; Fabiana Verdan Simões; Sílvia Maria de Sá Basílio Lins; Beatriz Guitton Renaud Baptista de Oliveira

Autores

Gilma Teresa Guimarães Perse Instituto Nacional de Câncer – Rio de Janeiro (RJ), Brasil. https://orcid.org/0000-0002-0311-6362
Rafael Tavares Jomar Instituto Nacional de Câncer – Rio de Janeiro (RJ), Brasil. https://orcid.org/0000-0002-4101-7138
Fabiana Verdan Simões Instituto Nacional de Câncer – Rio de Janeiro (RJ), Brasil. https://orcid.org/0000-0002-1109-9363
Sílvia Maria de Sá Basílio Lins Universidade Federal Fluminense – Niterói (RJ), Brasil. https://orcid.org/0000-0002-6717-9223
Beatriz Guitton Renaud Baptista de Oliveira Universidade Federal Fluminense – Niterói (RJ) https://orcid.org/0000-0001-7494-7457

Resumo

Objetivo: Analisar as evidências sobre o efeito dos agentes tópicos empregados para a prevenção da radiodermatite em pacientes com câncer. Método: Revisão sistemática de estudos clínicos randomizados duplos-cegos construída conforme recomendações do Joanna Briggs Institute e busca nas bases de dados MEDLINE/PubMed, CINAHL, LILACS, Web of Science, Embase, Scopus, além da literatura cinzenta. Utilizaram-se a ferramenta de avaliação crítica do JBI para ensaios clínicos randomizados para avaliar a possibilidade de viés, o Grading of Recommendations, Assessment, Development and Evaluation para a qualidade das evidências e o Gradepro® para recomendá-las. Resultados: Selecionaram-se 13 estudos que avaliaram diferentes agentes tópicos para prevenir a radiodermatite, a saber: corticosteroides, de ação antioxidante e fitoterápicos. A qualidade metodológica de cada estudo foi apropriada, mas a qualidade da evidência gerada pela reunião deles foi baixa, independentemente do tipo de agente tópico empregado, sugerindo que a confiança no seu efeito é limitada e tornando a força de recomendação fraca. Conclusão: Alguns agentes tópicos mostraram-se promissores para a prevenção de radiodermatite, mas as evidências aqui reunidas sobre a eficácia deles não permitem indicar seu uso para a prevenção de radiodermatite em pacientes com câncer.

Downloads

Não há dados estatísticos.

Referências

Cytlak UM, Dyer DP, Honeychurch J, Williams KJ, Travis MA, Illidge TM. Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. Nat Rev Immunol. 2022 Feb;22(2):124-38. https://doi.org/10.1038/s41577-021-00568-1

Ribuffo D, Lo Torto F, Marcasciano M. Radiodermatitis: prevention and treatment. In: Maruccia M, Giudice G. Textbook of plastic and reconstructive surgery. Berlin: Springer, Cham; 2022. p. 313-21. https://doi.org/10.1007/978-3-030-82335-1_20

Bastos LJD, Lanzillotti RS, Brandão MAG, Silva RC, Simões FV. Radiodermatitis: severity, predictive factors and discontinuation of radiotherapy in patients with anal and rectal cancer. Rev Esc Enferm USP. 2022 Jun 15;56:e20210378. https://doi.org/10.1590/1980-220X-REEUSP-2021-0378en

Rocha DM, Pedrosa AO, Oliveira AC, Benício CDAV, Santos AMR, Nogueira LT. Predictors and quality of life in patients with radiodermatitis: a longitudinal study. Acta Paul Enferm. 2021;34:eAPE01063. https://doi.org/10.37689/acta-ape/2021AO01063

Xie Y, Wang Q, Hu T, Chen R, Wang J, Chang H, Cheng J. Risk factors related to acute radiation dermatitis in breast cancer patients after radiotherapy: a systematic review and meta-analysis. Front Oncol. 2021 Nov 29;11:738851. https://doi.org/10.3389/fonc.2021.738851

Behroozian T, Milton L, Li N, Zhang L, Lou J, Karam I, Wronski M, McKenzie E, Mawdsley G, Razvi Y, Chow E, Ruschin M. Predictive factors associated with radiation dermatitis in breast cancer. Cancer Treat Res Commun. 2021;28:100403. https://doi.org/10.1016/j.ctarc.2021.100403

Vieira LAC, Menêses AG, Bontempo PSG, Simino GPR, Ferreira EB, Guerra ENS, Reis PED. Incidence of radiodermatitis in breast cancer patients during hypofractionated radiotherapy. Rev Esc Enferm USP. 2022 Dec 5;56:e20220173. https://doi.org/10.1590/1980-220X-REEUSP-2022-0173en

Bontempo PSM, Ciol MA, Menêses AG, Simino GPR, Ferreira EB, Reis PED. Acute radiodermatitis in cancer patients: incidence and severity estimates. Rev Esc Enferm USP. 2021 Apr 16;55:e03676. https://doi.org/10.1590/S1980-220X2019021703676

Martelletti LBSJ, Aguiar BRL, Vieira LAC, Menêses AG, Bontempo PSM, Ferreira EB, Reis PED. Incidence of acute radiodermatitis in women with breast cancer undergoing hypofractionated radiotherapy. Rev Bras Enferm. 2021 Sep 29;75(1):e20210118. http://doi.org/10.1590/0034-7167-2021-0118

Meghrajani CF, Co HS, Arcillas JG, Maaño CC, Cupino NA. A randomized, double-blind trial on the use of 1% hydrocortisone cream for the prevention of acute radiation dermatitis. Expert Rev Clin Pharmacol. 2016;9(3):483-91. https://doi.org/10.1586/17512433.2016.1126506

Rafati M, Ghasemi A, Saeedi M, Habibi E, Salehifar E, Mosazadeh M, Maham M. Nigella sativa L. for prevention of acute radiation dermatitis in breast cancer: a randomized, double-blind, placebo-controlled, clinical trial. Complement Ther Med. 2019 Dec.;47:102205. https://doi.org/10.1016/j.ctim.2019.102205

Sharp L, Finnilä K, Johansson H, Abrahamsson M, Hatschek T, Bergenmar M. No differences between Calendula cream and aqueous cream in the prevention of acute radiation skin reactions--results from a randomised blinded trial. Eur J Oncol Nurs. 2013 Aug;17(4):429-35. https://doi.org/10.1016/j.ejon.2012.11.003

Finkelstein S, Kanee L, Behroozian T, Wolf JR, van den Hurk C, Chow E, Bonomo P. Comparison of clinical practice guidelines on radiation dermatitis: a narrative review. Support Care Cancer. 2022 Jun;30(6):4663-74. https://doi.org/10.1007/s00520-022-06829-6

Wong RK, Bensadoun RJ, Boers-Doets CB, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Lacouture ME. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer. 2013;21(10):2933-48. https://doi.org/10.1007/s00520-013-1896-2

Behroozian T, Goldshtein D, Ryan Wolf J, van den Hurk C, Finkelstein S, Lam H, Patel P, Kanee L, Lee SF, Chan AW, Wong HCY, Caini S, Mahal S, Kennedy S, Chow E, Bonomo P; Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatology Study Group Radiation Dermatitis Guidelines Working Group. MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: part 1) systematic review. EClinicalMedicine. 2023 Mar 27;58:101886. https://doi.org/10.1016/j.eclinm.2023.101886

Behroozian T, Bonomo P, Patel P, Kanee L, Finkelstein S, van den Hurk C, Chow E, Wolf JR; Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatology Study Group Radiation Dermatitis Guidelines Working Group. Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations. Lancet Oncol. 2023 Apr;24(4):e172-e185. https://doi.org/10.1016/S1470-2045(23)00067-0

Aromataris E, Munn Z. JBI manual for evidence synthesis. Adelaide: JBI; 2020.

Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011 Apr;64(4):383-94. https://doi.org/10.1016/j.jclinepi.2010.04.026

Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Ciência e Tecnologia. Diretrizes metodológicas: sistema GRADE – manual de graduação da qualidade da evidência e força de recomendação para tomada de decisão em saúde [Internet]. Brasília: Ministério da Saúde; 2014 [acessado em 30 jun. 2022]. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_metodologicas_sistema_grade.pdf

Boström A, Lindman H, Swartling C, Berne B, Bergh J. Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study. Radiother Oncol. 2001 Jun;59(3):257-65. https://doi.org/10.1016/s0167-8140(01)00327-9

Glees JP, Mameghan-Zadeh H, Sparkes CG. Effectiveness of topical steroids in the control of radiation dermatitis: a randomised trial using 1% hydrocortisone cream and 0.05% clobetasone butyrate (Eumovate). Clin Radiol. 1979 Jul;30(4):397-403. https://doi.org/10.1016/s0009-9260(79)80217-2

Schmuth M, Wimmer MA, Hofer S, Sztankay A, Weinlich G, Linder DM, et al. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. Br J Dermatol. 2002 Jun;146(6):983-91. https://doi.org/10.1046/j.1365-2133.2002.04751.x

Ulff E, Maroti M, Serup J, Falkmer U. A potent steroid cream is superior to emollients in reducing acute radiation dermatitis in breast cancer patients treated with adjuvant radiotherapy. A randomised study of betamethasone versus two moisturizing creams. Radiother Oncol. 2013 Aug;108(2):287-92. https://doi.org/10.1016/j.radonc.2013.05.033

Rollmann DC, Novotny PJ, Petersen IA, Garces YI, Bauer HJ, Yan ES, Wahner-Roedler D, Vincent A, Sloan JA, Laack NNI. Double-blind, placebo-controlled pilot study of processed ultra emu oil versus placebo in the prevention of radiation dermatitis. Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):650-8. https://doi.org/10.1016/j.ijrobp.2015.02.028

Ben-David MA, Elkayam R, Gelernter I, Pfeffer RM. Melatonin for prevention of breast radiation dermatitis: a phase ii, prospective, double-blind randomized trial. Isr Med Assoc J. 2016 Mar-Apr;18(3-4):188-92. PMID: 27228641.

Ghasemi A, Ghashghai Z, Akbari J, Yazdani-Charati J, Salehifar E, Hosseinimehr SJ. Topical atorvastatin 1% for prevention of skin toxicity in patients receiving radiation therapy for breast cancer: a randomized, double-blind, placebo-controlled trial. Eur J Clin Pharmacol. 2019 Feb;75(2):171-8. https://doi.org/10.1007/s00228-018-2570-x

Karbasforooshan H, Hosseini S, Elyasi S, Pakdel AF, Karimi G. Topical silymarin administration for prevention of acute radiodermatitis in breast cancer patients: a randomized, double-blind, placebo-controlled clinical trial. Phytother Res 2019 Feb;33(2):379-86. https://doi.org/10.1002/ptr.6231

Aysan E, Idiz UO, Elmas L, Saglam EK, Akgun Z, Yucel SB. Effects of boron-based gel on radiation-induced dermatitis in breast cancer: a double-blind, placebo-controlled trial. J Invest Surg. 2017 Jun;30(3):187-92. https://doi.org/10.1080/08941939.2016.1232449

Williams MS, Burk M, Loprinzi CL, Hill M, Schomberg PJ, Nearhood K, O'Fallon JR, Laurie JA, Shanahan TG, Moore RL, Urias RE, Kuske RR, Engel RE, Eggleston WD. Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity. Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):345-9. https://doi.org/10.1016/s0360-3016(96)00320-3

Behroozian T, Milton LT, Shear NH, McKenzie E, Razvi Y, Karam I, Pon K, Lam H, Lam E, Chow E. Radiation dermatitis assessment tools used in breast cancer: a systematic review of measurement properties. Support Care Cancer. 2021 May;29:2265-78. https://doi.org/10.1007/s00520-020-05889-w